Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-29
2008-01-29
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S226200, C514S823000, C514S921000, C514S922000
Reexamination Certificate
active
07323461
ABSTRACT:
The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans. More specifically, the present invention concerns the use of MB or a related compound to prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor, such as sildenafil citrate, and a NO-donor, such as L-arginine, or an organic nitrate, such as nitroglycerin.
REFERENCES:
patent: 5854240 (1998-12-01), Kupfer et al.
Webster's New World Dictionary, Simon & Schuster, Inc., NY, 1988, p. 1067.
Goldstein I., Lue TF, Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998:338:1397-1404.
Webb D. J., Muirhead G. J., Wulff M., Sutton A., Levi R., and Dinsmore W. W. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. JACC 2000;36:25-31.
Jackson, G., Benjamin N., Jackson N., and Allen M. J. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13C-20C.
Webb D.J., Freestone S., Allen M. J., and Muirhead G. J. Sildenafil Citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagnoist. Am J Cardiol 1999;83:21C-28C.
Yoo K. Y., Kim H. S., Moon J. -D., and Lee J. Sildenafil (Viagra®) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. Anesth Analg 2002;94:1505-9.
Schalcher C., Schad K., Brunner-La Rocca H. P., Schindler R., Oechslin E., Scharf C., Suetsch G., Bertel O., Kiowski W. Interaction of sildenafil with cAMP-mediated vasodilation in vivo. Hypertension. 2002;40:763-7.
Ishikura, F., Beppu S., Hamada T., Khandheria B. K., Seward J. B., and Nehra A., Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation. 2000;102:2516-2521.
Kleinsasser A., Loeckinger A., Hoermann C., Puehringer F. Mutz N., Bartsch G., and Lindner K. H., Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 2001;163:339-343.
Herrmann H. C., Chang G., Klughertz B. D., and Mahoney P. D. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6.
Pfizer Inc., Customer Advocacy Medical Information, date unavailable.
Cheitlin, M.D., Hutter, A. M., Brindis, R. G., Ganz, P., Kaul S., Russell, R. O., and Zusman, R. M. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation. 1999;99:168-177.
Memis D., Karamanlioglu B., Yuksel M., Gemlik I., and Pamukcu Z., The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2002; 30(6) : 755-62. (one page).
Koelzow H., Gedney J. A., Baumann J., Snook N. J. and Bellamy M. C., The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 2002; 94; 824-9.
Ishizuka N et al.: “Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation,” Japanese Journal of Pharmacology 2000 Japan, vol. 84, No. 3, 2000, pp. 316-324.
Holzmann, S: “Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75).” Journal of Cardiovascular Pharmacology 1983 United States, vol. 5, No. 3, 1983, pp. 364-370.
Agha A M et al: “Sildenafil inhibits agonist-evoked rat uterine contractility: influence of guanylyl cyclase inhibition.” European Journal of Pharmacology 2001; 428(3) ; 343-8.
Jain N K et al: “Sildenafil—induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway.” Brain Research 2001; 909(1-2); 170-8.
Sakuma Ichiro et al: “Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.” European Journal of Pharamacology 2002; 437(3); 155-63.
Chandran S et al: “Nitric oxide: Concepts, current perspectives and future therapeutic implications.” Indian Journal of Pharmacology 1998 India; vol. 30, No. 6; 351-366.
O'Rourke M et al: “Sildenafil/Nitrate Interaction.” One page.
Robert M. Wallis, PhD. Jackie D. Corbin, PhD, Sharron H. Francis, PhD, and Peter Ellis, PhD, “Tissue Distribution of Phosphodiesterase Families and the Effects of Sildenafil on Tissue Cyclic Nucleotides, Platelet Function, and the Contractile Responses of Trabeculae Carneae and Aortic Rings in Vitro,” The American Journal of Cardiology, Mar. 4, 1999, 10 pages, vol. 83 (5A), Excerpta Medica Inc., Bridgewater, New Jersey.
Brouillette Denis
Juneau Martin
Tanguay Jean-François
Holland & Hart LLP
Montreal Heart Institute
Pak John
LandOfFree
Use of methylene blue and related compounds to prevent or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of methylene blue and related compounds to prevent or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of methylene blue and related compounds to prevent or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2815610